Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.6000 (-2.99%) ($2.5100 - $2.7900) on Thu. Apr. 21, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.21% (three month average) | RSI | 35 | Latest Price | $2.6000(-2.99%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.1% a day on average for past five trading days. | Weekly Trend | HTBX declines -3.7% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) IVE(99%) OIH(76%) XOP(71%) INDA(65%) SPY(64%) | Factors Impacting HTBX price | HTBX will decline at least -2.605% in a week (0% probabilities). BNDX(-60%) ACES(-35%) BWX(-27%) BND(-21%) TAN(-18%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.605% (StdDev 5.21%) | Hourly BBV | -1.3 () | Intraday Trend | -2.6% | | | |
|
Resistance Level | $2.91 | 5 Day Moving Average | $2.79(-6.81%) | 10 Day Moving Average | $2.8(-7.14%) | 20 Day Moving Average | $2.91(-10.65%) | To recent high | -17.5% | To recent low | 23.8% | Market Cap | $286m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |